SZSE:301096 (China)
Â
Class A
Â¥
33.84
-0.12 (-0.35%)
Apr 11
What is a stock summary page? Click here for an overview.
Business Description
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd
ISIN : CNE1000056N5
Share Class Description:
SZSE:301096: Class ACompare
Compare
Traded in other countries / regions
301096.China IPO Date
2021-12-20Description
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is a pharmaceutical technology research and development company. The company's business covers drug discovery, pharmaceutical research, clinical research, and registration application.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.77 | |||||
| Equity-to-Asset | 0.74 | |||||
| Debt-to-Equity | 0.22 | |||||
| Debt-to-EBITDA | 2.87 | |||||
| Interest Coverage | 29.37 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | 3.16 | |||||
| Beneish M-Score | -1.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 54.2 | |||||
| 3-Year EBITDA Growth Rate | 51.7 | |||||
| 3-Year EPS without NRI Growth Rate | 48.4 | |||||
| 3-Year FCF Growth Rate | -30.5 | |||||
| 3-Year Book Growth Rate | 80.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 9 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 36.14 | |||||
| 9-Day RSI | 36.43 | |||||
| 14-Day RSI | 38.37 | |||||
| 3-1 Month Momentum % | 7.69 | |||||
| 6-1 Month Momentum % | -10.46 | |||||
| 12-1 Month Momentum % | -47.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.94 | |||||
| Quick Ratio | 1.75 | |||||
| Cash Ratio | 0.56 | |||||
| Days Inventory | 111.29 | |||||
| Days Sales Outstanding | 98.73 | |||||
| Days Payable | 202.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.88 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| Forward Dividend Yield % | 0.88 | |||||
| 5-Year Yield-on-Cost % | 0.88 | |||||
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -8.86 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 61.22 | |||||
| Operating Margin % | 23.19 | |||||
| Net Margin % | 20.69 | |||||
| FCF Margin % | -67.63 | |||||
| ROE % | 7.8 | |||||
| ROA % | 5.71 | |||||
| ROIC % | 9.09 | |||||
| 3-Year ROIIC % | 10.73 | |||||
| ROC (Joel Greenblatt) % | 11 | |||||
| ROCE % | 7.33 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.27 | |||||
| Forward PE Ratio | 17.09 | |||||
| PE Ratio without NRI | 15.12 | |||||
| Shiller PE Ratio | 43.95 | |||||
| PEG Ratio | 0.28 | |||||
| PS Ratio | 3.58 | |||||
| PB Ratio | 1.33 | |||||
| Price-to-Tangible-Book | 1.38 | |||||
| EV-to-EBIT | 18.32 | |||||
| EV-to-EBITDA | 18.32 | |||||
| EV-to-Revenue | 3.76 | |||||
| EV-to-FCF | -5.43 | |||||
| Price-to-GF-Value | 0.38 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.57 | |||||
| Price-to-Graham-Number | 0.96 | |||||
| Price-to-Net-Current-Asset-Value | 6.15 | |||||
| Earnings Yield (Greenblatt) % | 5.46 | |||||
| FCF Yield % | -18.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 1,025.121 | ||
| EPS (TTM) (Â¥) | 1.96 | ||
| Beta | 1.46 | ||
| 3-Year Sharpe Ratio | -0.49 | ||
| 3-Year Sortino Ratio | -0.68 | ||
| Volatility % | 49.46 | ||
| 14-Day RSI | 38.37 | ||
| 14-Day ATR (Â¥) | 1.614279 | ||
| 20-Day SMA (Â¥) | 36.506 | ||
| 12-1 Month Momentum % | -47.72 | ||
| 52-Week Range (Â¥) | 30.6 - 76.17 | ||
| Shares Outstanding (Mil) | 109.23 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hangzhou Bio-Sincerity Pharma-Tech Co Ltd Frequently Asked Questions
What is Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096)'s stock price today?
The current price of SZSE:301096 is ¥33.84. The 52 week high of SZSE:301096 is ¥76.17 and 52 week low is ¥30.60.
When is next earnings date of Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096)?
The next earnings date of Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096) is .
Does Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096) pay dividends? If so, how much?
The Dividend Yield %  of Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096) is 0.88% (As of Today), Highest Dividend Payout Ratio of Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096) was 0.38. The lowest was 0.13. And the median was 0.36. The  Forward Dividend Yield % of Hangzhou Bio-Sincerity Pharma-Tech Co Ltd(SZSE:301096) is 0.88%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers